Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country.
Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...
Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...
The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...
The United States Tumor Profiling Market is projected to surge from US$ 3.41 billion in 2024 to US$ 7.44 billion by 2033, ...
Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...
On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...
10X Genomics Inc. sued Illumina Inc., accusing it of infringing patents covering single-cell genetic sequencing and spatial technology. Illumina’s products and systems infringe a total of nine patents ...
Boston Children's Hospital, along with Broad Clinical Labs and Roche Sequencing Solutions, has demonstrated that rapid genomic sequencing and interpretation are achievable in a matter of hours. This ...
TEL AVIV, Israel & LEHI, Utah & HOUSTON & FREMONT, Calif.--(BUSINESS WIRE)--MyHeritage, the leading global platform for family history and DNA testing, announced today a landmark move to Whole Genome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback